Pharmaceutical and Toxicological Properties of Engineered Nanomaterials for Drug Delivery

被引:42
作者
Palombo, Matthew [1 ,2 ]
Deshmukh, Manjeet [1 ,3 ]
Myers, Daniel [1 ]
Gao, Jieming [1 ]
Szekely, Zoltan [1 ]
Sinko, Patrick J. [1 ]
机构
[1] Rutgers State Univ, Sch Pharm, Piscataway, NJ 08854 USA
[2] GlaxoSmithKline, King Of Prussia, PA 19406 USA
[3] Icahn Sch Med Mt Sinai, Hess Ctr Sci & Med, New York, NY 10029 USA
来源
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 | 2014年 / 54卷
关键词
nanotechnology; drug delivery systems; biodistribution; elimination; toxicity; PROTEIN SURFACE INTERACTIONS; POLYETHYLENE-GLYCOL; POLY(ETHYLENE GLYCOL); COVALENT ATTACHMENT; FLASH NANOPRECIPITATION; RIGID MICROPARTICLES; PLGA NANOPARTICLES; CIRCULATING LIFE; PAMAM DENDRIMERS; TOXICITY;
D O I
10.1146/annurev-pharmtox-010611-134615
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Novel engineered nanomaterials (ENMs) are being developed to enhance therapy. The physicochemical properties of ENMs can be manipulated to control/direct biodistribution and target delivery, but these alterations also have implications for toxicity. It is well known that size plays a significant role in determining ENM effects since simply nanosizing a safe bulk material can render it toxic. However, charge, shape, rigidity, and surface modifications also have a significant influence on the biodistribution and toxicity of nanoscale drug delivery systems (NDDSs). In this review, NDDSs are considered in terms of platform technologies, materials, and physical properties that impart their pharmaceutical and toxicological effects. Moving forward, the development of safe and effective nanomedicines requires standardized protocols for determining the physical characteristics of ENMs as well as assessing their potential long-term toxicity. When such protocols are established, the remarkable promise of nanomedicine to improve the diagnosis and treatment of human disease can be fulfilled.
引用
收藏
页码:581 / 598
页数:18
相关论文
共 116 条
[1]  
ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
[2]  
ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578
[3]  
ABUCHOWSKI A, 1979, CANCER TREAT REP, V63, P1127
[4]   PREPARATION AND PROPERTIES OF POLYETHYLENE GLYCOL TRYPSIN ADDUCTS [J].
ABUCHOWSKI, A ;
DAVIS, FF .
BIOCHIMICA ET BIOPHYSICA ACTA, 1979, 578 (01) :41-46
[5]   Effects of nanomaterial physicochemical properties on in vivo toxicity [J].
Aillon, Kristin L. ;
Xie, Yumei ;
El-Gendy, Nashwa ;
Berkland, Cory J. ;
Forrest, M. Laird .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (06) :457-466
[6]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[7]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[8]  
[Anonymous], CONS WHETH FDA REG P
[9]  
Armstrong JK, 2003, AM SOC HEM ANN M 45
[10]   Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients [J].
Armstrong, Jonathan K. ;
Hempel, Georg ;
Koling, Susanne ;
Chan, Linda S. ;
Fisher, Timothy ;
Meiselman, Herbert J. ;
Garratty, George .
CANCER, 2007, 110 (01) :103-111